NO973745D0 - Nukleinsyreholdig preparat, dets fremstilling og anvendelse - Google Patents

Nukleinsyreholdig preparat, dets fremstilling og anvendelse

Info

Publication number
NO973745D0
NO973745D0 NO973745A NO973745A NO973745D0 NO 973745 D0 NO973745 D0 NO 973745D0 NO 973745 A NO973745 A NO 973745A NO 973745 A NO973745 A NO 973745A NO 973745 D0 NO973745 D0 NO 973745D0
Authority
NO
Norway
Prior art keywords
nucleic acid
preparation
vivo
transfecting
compound
Prior art date
Application number
NO973745A
Other languages
English (en)
Norwegian (no)
Other versions
NO973745L (no
Inventor
Gerardo Byk
Daniel Scherman
Bertrand Schwartz
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9476267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO973745(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO973745L publication Critical patent/NO973745L/no
Publication of NO973745D0 publication Critical patent/NO973745D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO973745A 1995-02-17 1997-08-14 Nukleinsyreholdig preparat, dets fremstilling og anvendelse NO973745D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9501865A FR2730637B1 (fr) 1995-02-17 1995-02-17 Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
PCT/FR1996/000248 WO1996025508A1 (fr) 1995-02-17 1996-02-15 Compositions contenant des acides nucleiques, preparation et utilisation

Publications (2)

Publication Number Publication Date
NO973745L NO973745L (no) 1997-08-14
NO973745D0 true NO973745D0 (no) 1997-08-14

Family

ID=9476267

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973745A NO973745D0 (no) 1995-02-17 1997-08-14 Nukleinsyreholdig preparat, dets fremstilling og anvendelse

Country Status (18)

Country Link
US (2) US5945400A (cs)
EP (1) EP0809705B1 (cs)
JP (1) JPH11500431A (cs)
KR (1) KR19980702200A (cs)
AT (1) ATE313642T1 (cs)
AU (1) AU706643B2 (cs)
BR (1) BR9607383A (cs)
CA (1) CA2211162A1 (cs)
CZ (1) CZ293269B6 (cs)
DE (1) DE69635609T2 (cs)
FI (1) FI973363A (cs)
FR (1) FR2730637B1 (cs)
HU (1) HU223263B1 (cs)
IL (1) IL117144A0 (cs)
NO (1) NO973745D0 (cs)
SK (1) SK281543B6 (cs)
WO (1) WO1996025508A1 (cs)
ZA (1) ZA961255B (cs)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5939401A (en) * 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
JP2002514892A (ja) * 1995-06-08 2002-05-21 コブラ セラピューティクス リミテッド 遺伝子治療における合成ウイルス様粒子の使用
FR2741066B1 (fr) 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2756491B1 (fr) * 1996-11-29 1999-01-08 Rhone Poulenc Rorer Sa Composition transfectante utile en therapie genique associan t a un virus recombinant incorporant un acide nucleique exog ene, un agent de transfection non viral et non plasmidique
FR2750704B1 (fr) 1996-07-04 1998-09-25 Rhone Poulenc Rorer Sa Procede de production d'adn therapeutique
CN1181422A (zh) * 1996-10-31 1998-05-13 上海市肿瘤研究所 与生长因子受体结合的多肽所构建的基因转移载体
US7008776B1 (en) * 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
AP1313A (en) 1996-12-06 2004-10-04 Aventis Pharma Inc Polypeptides encoded by a human lipase-like gene, composition and method.
US6884430B1 (en) 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
BR9808697A (pt) 1997-04-28 2000-07-11 Rhone Poulenc Rorer Sa Processo para inibir o crescimento de um tumor, vetor de adenovìrus defeituoso, vetor de vìrus, uso do mesmo, e, composição farmacêutica
FR2763943B1 (fr) * 1997-05-28 1999-07-09 Rhone Poulenc Rorer Sa Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
CN1289371A (zh) 1998-01-30 2001-03-28 阿文蒂斯药物股份有限公司 对还原条件敏感的转染化合物,含有它们的药物组合物及其应用
FR2774394B1 (fr) * 1998-01-30 2002-04-26 Rhone Poulenc Rorer Sa Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
CN1348498A (zh) * 1998-12-03 2002-05-08 阿文蒂斯药物股份有限公司 新的核酸转移试剂、含有它们的组合物及其应用
FR2786700B1 (fr) * 1998-12-03 2002-12-06 Aventis Pharma Sa Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs utilisations
US6441156B1 (en) 1998-12-30 2002-08-27 The United States Of America As Represented By The Department Of Health And Human Services Calcium channel compositions and methods of use thereof
US9034329B2 (en) * 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
AU3703100A (en) * 1999-02-22 2000-09-14 Georgetown University Antibody fragment-targeted immunoliposomes for systemic gene delivery
US7780882B2 (en) * 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
GB9918670D0 (en) 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
EP1818409A1 (en) * 1999-09-09 2007-08-15 CureVac GmbH Transfer of mRNAusing polycationic compounds
CA2390716A1 (en) * 1999-09-24 2001-04-05 Alan D. King Process for enhancing electric field-mediated delivery of biological materials into cells
EP1276500B1 (en) 2000-03-13 2011-06-08 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99/hec2
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
NZ521564A (en) * 2000-04-12 2004-06-25 Implyx Ltd Compositions for drug delivery
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20040142474A1 (en) * 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
FR2814370B1 (fr) * 2000-09-22 2004-08-20 Centre Nat Rech Scient Utilisation d'un complexe acide nucleique/pei pour le ciblage de cellules souches du cerveau
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
US7060442B2 (en) 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
EP1355918B9 (en) 2000-12-28 2012-01-25 Wyeth LLC Recombinant protective protein from $i(streptococcus pneumoniae)
US20030125239A1 (en) * 2001-02-02 2003-07-03 Andrea Crisanti Compositions for drug delivery
WO2002063026A1 (en) * 2001-02-08 2002-08-15 Geneporter, Inc. Complexes and components thereof for introducing polynucleotides into eukaryotic cells
WO2002066615A2 (en) 2001-02-20 2002-08-29 Rheogene, Inc. Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
ES2392508T3 (es) 2001-02-20 2012-12-11 Intrexon Corporation Receptores X retinoides quiméricos y su uso en un sistema inducible de expresión génica basado en receptores de ecdisona novedoso
US8715959B2 (en) 2001-02-20 2014-05-06 Intrexon Corporation Substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
MXPA03007493A (es) 2001-02-20 2004-10-15 Rheogene Holdings Inc Nuevo sistema de expresion genetica inducible a base de receptor de ecdisona/receptor x retinoide de invertebrado.
US20030039660A1 (en) 2001-03-02 2003-02-27 The Rockefeller University Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
US8216585B2 (en) 2001-05-25 2012-07-10 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
WO2002100435A1 (en) * 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
FR2829136B1 (fr) * 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
US7919269B2 (en) 2001-09-26 2011-04-05 Intrexon Corporation Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
MXPA04002810A (es) 2001-09-26 2005-06-06 Rheogene Holdings Inc Acidos nucleicos receptores de ecdisona de saltarilla, polipeptidos, y sus usos.
US20040023910A1 (en) * 2001-09-28 2004-02-05 Zhiming Zhang Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2003205545A1 (en) 2002-01-17 2003-07-30 York Refrigeration Aps Submerged evaporator with integrated heat exchanger
US7037520B2 (en) * 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
KR101152561B1 (ko) 2002-09-27 2012-06-01 파우더젝트 리서치 리미티드 핵산 코팅된 입자
AU2004204456A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
US7304161B2 (en) * 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
JP2007531498A (ja) * 2003-07-15 2007-11-08 セダーズ−シナイ メディカル センター 疾患の診断、処置および予防におけるプレイオトロフィンの使用
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
JP4838722B2 (ja) 2003-10-24 2011-12-14 ゲンシア コーポレーション ポリヌクレオチドを送達する方法、及び送達用組成物
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US7432057B2 (en) 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
CA2605574A1 (en) 2004-04-20 2005-11-03 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
JP5128273B2 (ja) 2004-04-27 2013-01-23 ガラパゴス・ナムローゼ・フェンノートシャップ 未分化哺乳動物細胞の分化を骨芽細胞へと誘導するための方法、作用物質、及び化合物スクリーニングアッセイ
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
ATE534736T1 (de) 2004-06-14 2011-12-15 Galapagos Nv Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen
JP5022217B2 (ja) 2004-06-18 2012-09-12 デューク ユニバーシティー 匂い物質受容体のモジュレーター
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
US7604798B2 (en) 2004-07-15 2009-10-20 Northwestern University Methods and compositions for importing nucleic acids into cell nuclei
ATE527281T1 (de) 2004-07-16 2011-10-15 Us Gov Health & Human Serv Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
AU2006259415B2 (en) * 2005-06-15 2012-08-30 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
CN101437539B (zh) 2005-07-05 2013-10-02 康奈尔研究基金会（有限公司） 通过干扰cd99l2阻断白细胞迁出和炎症
WO2007028147A2 (en) 2005-09-01 2007-03-08 Philadelphia Health & Education Corporation D.B.A. Drexel University College Of Medicin Identification of a prostatic intraepithelial neoplasia (pin)-specific gene and protein (pin-1) useful as a diagnostic treatment for prostate cancer
EP2023897A4 (en) * 2006-05-15 2013-04-03 Univ Georgetown PREPARATION OF ANTIBODY OR ANTIBODY FRAGMENT-TUNED IMMUNOLIPOSOMES FOR SYSTEMIC ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC ACTIVITIES AND USES THEREOF
KR100857389B1 (ko) 2006-06-30 2008-09-11 (주)아모레퍼시픽 Ａｐ-ｇｒｒ 펩티드 또는 ａｐ-ｇｒｒ 펩티드를 포함하는펩티드사슬 및 이를 포함하는 약물전달담체
MY151438A (en) 2006-07-28 2014-05-30 Sanofi Aventis Compositions and method for treatment of tumors
CA2665403C (en) 2006-10-04 2015-06-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008137993A1 (en) 2007-05-08 2008-11-13 Duke University Compositions and methods for characterizing and regulating olfactory sensation
CA2689137C (en) 2007-05-29 2017-05-02 Intrexon Corporation Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
CA2690685A1 (en) 2007-06-20 2008-12-24 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
US20090069266A1 (en) 2007-06-27 2009-03-12 Northwestern University Methods and compositions for nucleic acid transfer into cells
BRPI0814558A2 (pt) * 2007-07-09 2015-01-06 Univ Georgetown Métodos para aagerar resposta imune usando liberação de ácido nucléico mediada por lipossoma catiônico
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
JP2010536373A (ja) 2007-08-23 2010-12-02 イントレキソン コーポレーション 疾患を診断するための方法および組成物
JP2010539245A (ja) * 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
BRPI0817009A2 (pt) * 2007-09-17 2014-10-07 Rohm & Haas Sistema de expressão de gene para a expressão controlável de resposta ao etileno em uma célula de planta, composição, e, métodos para produzir uma planta transgênica, e para modular sensibilidade ao etileno em uma planta.
EP2042193A1 (en) 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
CA2715080C (en) 2007-09-28 2021-09-28 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
CA2702058A1 (en) 2007-10-08 2009-04-16 Intrexon Corporation Engineered dendritic cells and uses for the treatment of cancer
FR2928373B1 (fr) 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
WO2010029118A1 (en) 2008-09-11 2010-03-18 Biofocus Dpi B.V. Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
CN102203122A (zh) 2008-11-05 2011-09-28 惠氏有限责任公司 用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物
AU2009311667B2 (en) 2008-11-07 2016-04-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
WO2010094732A1 (en) 2009-02-19 2010-08-26 Biofocus Dpi B.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
WO2010094734A2 (en) 2009-02-19 2010-08-26 Biofocus Dpi B.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
EP2398481A2 (en) 2009-02-19 2011-12-28 Galapagos N.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
EP2414830A2 (en) 2009-03-31 2012-02-08 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
WO2010115841A1 (en) 2009-04-01 2010-10-14 Galapagos Nv Methods and means for treatment of osteoarthritis
CA2758542A1 (en) 2009-04-17 2010-10-21 New York University Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
US9186370B2 (en) 2010-03-19 2015-11-17 University Of South Alabama Methods and compositions for the treatment of cancer
WO2011119773A1 (en) 2010-03-23 2011-09-29 Roeth Jeremiah F Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
SI3246044T2 (sl) 2010-08-23 2024-06-28 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
ES2585328T5 (es) 2010-09-10 2022-12-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
CA2819552C (en) 2010-12-09 2023-09-26 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
CN103534355A (zh) 2011-03-04 2014-01-22 英特瑞克斯顿股份有限公司 条件性表达蛋白质的载体
DK2691443T3 (da) 2011-03-28 2021-05-03 Massachusetts Inst Technology Konjugerede lipomerer og anvendelser af disse
US9458456B2 (en) 2011-04-01 2016-10-04 University Of South Alabama Methods and compositions for the diagnosis, classification, and treatment of cancer
EP2546358A1 (en) 2011-07-15 2013-01-16 Laboratorios Del. Dr. Esteve, S.A. Methods and reagents for efficient control of HIV progression
BR112014006535A2 (pt) 2011-09-20 2017-03-28 Univ North Carolina Chapel Hill regulação dos canais de sódio através das proteínas plunc
WO2013053765A1 (en) 2011-10-11 2013-04-18 Proyecto De Biomedicina Cima, S.L. A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
UA119028C2 (uk) 2011-10-27 2019-04-25 Массачусеттс Інстітьют Оф Текнолоджі Функціоналізовані на n-кінці амінокислотні похідні, здатні утворювати мікросфери, що інкапсулюють лікарський засіб
NO2788478T3 (cs) 2011-12-09 2018-01-20
US9464291B2 (en) 2012-01-06 2016-10-11 University Of South Alabama Methods and compositions for the treatment of cancer
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
EP2698377A1 (en) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
WO2014139884A2 (en) 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis
JP2016522675A (ja) 2013-03-14 2016-08-04 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター
EP2972322B1 (en) 2013-03-14 2019-03-06 Galapagos NV Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases
AU2014227571B2 (en) 2013-03-15 2017-02-02 Intrexon Corporation Boron-containing diacylhydrazines
US20160130585A1 (en) 2013-05-28 2016-05-12 The Johns Hopkins University Aptamers for the treatment of sickle cell disease
EP3041502A2 (en) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR101605421B1 (ko) 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
EP3194359B1 (en) 2014-09-17 2020-04-08 Intrexon Corporation Boron-containing diacylhydrazine compounds
KR102554850B1 (ko) 2015-02-06 2023-07-13 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
TW201710503A (zh) 2015-06-12 2017-03-16 長庚醫療財團法人林口長庚紀念醫院 新穎多核苷酸、載體、醫藥組成物以及其用途
LT3310764T (lt) 2015-06-19 2023-06-12 Massachusetts Institute Of Technology Alkenilu pakeisti 2,5-piperazindionai ir jų panaudojimas kompozicijose, skirtose agento pristatymui į subjektą ar ląstelę
ES2907486T3 (es) 2015-09-24 2022-04-25 Univ North Carolina Chapel Hill Métodos y composiciones para reducir metástasis
EP3347373A1 (en) 2015-10-10 2018-07-18 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
WO2017147128A1 (en) 2016-02-22 2017-08-31 The University Of North Carolina At Chapel Hill Peptide inhibitors of calcium channels
WO2018089527A1 (en) 2016-11-09 2018-05-17 Intrexon Corporation Frataxin expression constructs
WO2018096457A1 (en) 2016-11-22 2018-05-31 Kabushiki Kaisha Toshiba Nucleic acid condensing peptide, nucleic acid condensing peptide set, nucleic acid delivery carrier, nucleic acid delivery method, cell production method, cell detection method and kit
IL267733B2 (en) 2017-01-31 2023-10-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
US20200393446A1 (en) 2017-12-08 2020-12-17 Centre National De La Recherche Scientifique (Cnrs) Bioluminescent screening test for detecting cell cytolysis
EP3539975A1 (en) 2018-03-15 2019-09-18 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Micropeptides and uses thereof
MX2021001672A (es) 2018-08-10 2021-07-15 Eutilex Co Ltd Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car.
SG11202109225WA (en) 2019-03-08 2021-09-29 Obsidian Therapeutics Inc Cd40l compositions and methods for tunable regulation
WO2020212756A2 (en) 2019-04-18 2020-10-22 Genkin Dmitry Dmitrievich Reprogramming of polymorphonuclear leukocytes
KR20220139319A (ko) 2020-01-08 2022-10-14 옵시디안 테라퓨틱스, 인크. 조정 가능한 전사의 조절을 위한 조성물 및 방법
EP3885440A1 (en) 2020-03-26 2021-09-29 Splicebio, S.L. Split inteins and their uses
WO2023242436A1 (en) 2022-06-17 2023-12-21 Danmarks Tekniske Universitet Allergy vaccines based on consensus allergens

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0140308B2 (en) 1983-10-20 2001-10-17 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition utilizing mRNA interfering complementary RNA
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
FR2602790B1 (fr) 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
ATE115999T1 (de) 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
FR2646161B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5286634A (en) 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
DE59106279D1 (de) * 1990-05-18 1995-09-21 Genentech Inc Neue protein-polykation-konjugate.
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1993019768A1 (en) * 1992-04-03 1993-10-14 The Regents Of The University Of California Self-assembling polynucleotide delivery system
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
FR2704234B1 (fr) 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
SG54115A1 (en) 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
FR2704556B1 (fr) 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations

Also Published As

Publication number Publication date
ATE313642T1 (de) 2006-01-15
SK111897A3 (en) 1998-02-04
FR2730637A1 (fr) 1996-08-23
HU223263B1 (hu) 2004-04-28
EP0809705B1 (fr) 2005-12-21
FR2730637B1 (fr) 1997-03-28
BR9607383A (pt) 1997-11-25
HUP9801207A3 (en) 2000-12-28
ZA961255B (en) 1996-08-27
DE69635609T2 (de) 2006-09-14
FI973363A0 (fi) 1997-08-15
NO973745L (no) 1997-08-14
IL117144A0 (en) 1996-06-18
WO1996025508A1 (fr) 1996-08-22
JPH11500431A (ja) 1999-01-12
DE69635609D1 (de) 2006-01-26
HUP9801207A2 (hu) 1998-08-28
CZ259297A3 (en) 1997-11-12
KR19980702200A (ko) 1998-07-15
US6200956B1 (en) 2001-03-13
FI973363A (fi) 1997-08-15
AU706643B2 (en) 1999-06-17
MX9706016A (es) 1997-11-29
CZ293269B6 (cs) 2004-03-17
EP0809705A1 (fr) 1997-12-03
CA2211162A1 (fr) 1996-08-22
SK281543B6 (sk) 2001-04-09
AU4835396A (en) 1996-09-04
US5945400A (en) 1999-08-31

Similar Documents

Publication Publication Date Title
NO973745L (no) Nukleinsyreholdig preparat, dets fremstilling og anvendelse
BRPI9710372B8 (pt) composto, e, composição farmacêutica.
FI962799A0 (fi) Nukleiinihappoja sisältävä valmiste, sen valmistus ja käyttö
BR9911871B1 (pt) derivados de ácido fenoxiacético e composições farmacêuticas contendo os mesmos.
EE200100558A (et) Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
AR024944A1 (es) Amidas de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y su preparacion
BR9711046A (pt) Ligando relacionado a fator de necrose de tumor.
BR9808140A (pt) Formulação unitária
BR9800913A (pt) Promotor de gene cdc25b, preparação e uso do mesmo.
HUP0001693A2 (hu) Alfa-hidroxisavak és/vagy aromás o-hidroxisavak alacsony molekulatömegű oligomer észtereinek alkalmazása kozmetikai készítményekben
BR9812780A (pt) 2-aril-3-aroilbenzo[b]tiofenos úteis para o tratamento de sìndrome da perda de estrogênio
WO1999038821A3 (fr) Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications
AU5428700A (en) Acrylic acid derivatives, use of the same and intermediates for the preparation thereof
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
BR9811579A (pt) Processo para preparação de ácidos 3-ciano-2,4-dialógeno-5-fluorobenzóicos
BG104452A (en) New derivatives of the methylenebisphosphonic acid
HUP0100957A3 (en) 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same, their use and pharmaceutical compositions containing them
ITRM930686A1 (it) Impiego di altrenogest per la preparazione di composizioni veterinarie iniettabili.
FI944227A0 (fi) 1,2,3,4-tetrahydrokinolin-8-sulfonihapot ja -happokloridit, niiden valmistus ja käyttö synteesin välituotteina
WO2001039725A3 (en) Drug preparations
UY24851A1 (es) Derivados de ácidos n-acil-alfa-aminados
MX9801920A (es) Composicion farmaceutica util para la transfeccion de acidos nucleicos y sus usos.
AU8766398A (en) Novel pharmaceutical alpha-keto carboxylic acid compositions, method of making and use thereof
HUP0104007A3 (en) Pyrimidinyloxy derivatives of new carboxylic acid derivatives carrying keto side-chain, pharmaceutical compositions containing them, their use and their intermediates
IT1320770B1 (it) Processo per la sintesi del metil estere dell'acido 1-metil-5-(4-metilbenzoil)-pirrol-2-acetico.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application